Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

PF-299804 Shows Trend Toward Survival Benefit vs. Tarceva

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

I've previously described the novel "pan-HER inhibitor" PF-299804 and even the randomized phase II trial of PF-299 vs. the EGFR tyrosine kinase inhibitor Tarceva that showed a higher response rate (RR) and longer progression-free survival (PFS) with PF-299. At the World Conference on Lung Cancer in Amsterdam, the investigators also presented updated results from this trial that showed a trend toward a survival benefit with PF-299 as well. This was a trial of 188 patients with previously treated advanced NSCLC, not selected for having an EGFR mutation, being never smokers, or any other specific subset. The prior post describes many of the results, including the modestly greater side effects with PF-299 that accompanied the improvement in RR and PFS. In the update of the results, PFS is still significantly better with PF-299, and they also specifically focused on the 2/3 of patients who were KRAS "wild type" (no mutation), who are shown in the curves on the right in the figure below: pfs-overall-and-in-kras-wt (click on image to enlarge)

As you can see, there was a pretty convincing (and statistically significant) shift to more prolonged PFS in entire patient population that was even more pronounced in the patients who were KRAS wild type. As in the earlier presentation of the results from the trial, a review of the various subsets of patients in the trial showed that nearly all subgroups trended toward more benefit in PFS with PF-299 compared with Tarceva: pfs-forest-plot In the figure above, the boxes situated to the left of the vertical line on the right side represent improvement with PF299 over Tarceva (and the more to the left, the stronger the benefit). Nearly all groups fall clearly to the left of the vertical line. At the Amsterdam meeting, we also got results on overall survival (OS), which showed a trend (not statistically) significant that also favored PF-299, as shown in the figure below: os-pf299-vs-erlotinib Though it shows only a trend in the direction of more favorable direction, this was only a relatively small phase II trial, for which showing a statistically significant improvement in OS would have been very ambitious. Overall, the investigators were very encouraged by these findings, but the definitive answer about the potential benefit of PF-299804 over Tarceva will ultimately be answered by the results of the phase III trial (ARCHER 1009) with the same general study design that is currently ongoing. This trial will be looking for a significant improvement in PFS in both the general population of all NSCLC patients and in the subset of patients with KRAS wild type. I'll look forward to presenting results of that trial in coming years, and this could lead to a new agent becoming available for advanced NSCLC.

Next Previous link

Previous PostNext Post

Related Content

Image
Patient Education Ambassadors 2023-24
Video
Drs. Matthew Kurian, Karan Jatwani, and Karine Tawagi discuss risk factors for developing prostate cancer, PSA test in prostate cancer screening, biopsies in prostate cancer, among other relevant information about prostate cancer. To watch the full playlist click here.  
Image
Patient Education Ambassadors 2023-24
Video
La Dra. Ivy Riano analiza las diversas opciones de tratamiento para pacientes con cáncer y analiza las diversas opciones de tratamiento para pacientes con cáncer. Para ver la lista completa de videos da click aquí.

Forum Discussions

Hi ramosking,  Welcome to Grace.  I'm sorry you're suffering.  It doesn't sound like you have a pancoast tumor. It does seem like you should see your PCP or a pulmonologist for...

Hey, So I went to the Doctor and explained all my symptoms I was having, They did some examining by listening to my lungs with a stethoscope, They said my lungs...

I hope you find some help through your doc or PT. 

Take care,

Janine

Hi Revtoby, Welcome to Grace.  I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Recent Comments

JOIN THE CONVERSATION
I hope you find some help…
By JanineT GRACE … on
Went to doctor
By ramosking on
Hi ramosking,  Welcome to…
By JanineT GRACE … on
Hi Mackensie,  I'm sorry…
By JanineT GRACE … on